S&P 500   4,075.83 (+0.62%)
DOW   33,031.83 (+0.53%)
QQQ   317.65 (+0.62%)
AAPL   162.73 (+0.23%)
MSFT   283.54 (-0.18%)
META   209.95 (+1.02%)
GOOGL   102.64 (+1.73%)
AMZN   102.63 (+0.62%)
TSLA   200.25 (+2.55%)
NVDA   274.04 (+0.08%)
NIO   10.51 (+0.48%)
BABA   102.47 (-0.88%)
AMD   96.53 (-1.38%)
T   19.11 (+0.16%)
F   12.47 (+1.46%)
MU   61.23 (-2.95%)
CGC   1.78 (+0.85%)
GE   94.93 (+0.94%)
DIS   98.93 (+0.85%)
AMC   4.96 (-0.20%)
PFE   40.54 (+0.40%)
PYPL   74.94 (+0.74%)
NFLX   341.11 (+0.79%)
S&P 500   4,075.83 (+0.62%)
DOW   33,031.83 (+0.53%)
QQQ   317.65 (+0.62%)
AAPL   162.73 (+0.23%)
MSFT   283.54 (-0.18%)
META   209.95 (+1.02%)
GOOGL   102.64 (+1.73%)
AMZN   102.63 (+0.62%)
TSLA   200.25 (+2.55%)
NVDA   274.04 (+0.08%)
NIO   10.51 (+0.48%)
BABA   102.47 (-0.88%)
AMD   96.53 (-1.38%)
T   19.11 (+0.16%)
F   12.47 (+1.46%)
MU   61.23 (-2.95%)
CGC   1.78 (+0.85%)
GE   94.93 (+0.94%)
DIS   98.93 (+0.85%)
AMC   4.96 (-0.20%)
PFE   40.54 (+0.40%)
PYPL   74.94 (+0.74%)
NFLX   341.11 (+0.79%)
S&P 500   4,075.83 (+0.62%)
DOW   33,031.83 (+0.53%)
QQQ   317.65 (+0.62%)
AAPL   162.73 (+0.23%)
MSFT   283.54 (-0.18%)
META   209.95 (+1.02%)
GOOGL   102.64 (+1.73%)
AMZN   102.63 (+0.62%)
TSLA   200.25 (+2.55%)
NVDA   274.04 (+0.08%)
NIO   10.51 (+0.48%)
BABA   102.47 (-0.88%)
AMD   96.53 (-1.38%)
T   19.11 (+0.16%)
F   12.47 (+1.46%)
MU   61.23 (-2.95%)
CGC   1.78 (+0.85%)
GE   94.93 (+0.94%)
DIS   98.93 (+0.85%)
AMC   4.96 (-0.20%)
PFE   40.54 (+0.40%)
PYPL   74.94 (+0.74%)
NFLX   341.11 (+0.79%)
S&P 500   4,075.83 (+0.62%)
DOW   33,031.83 (+0.53%)
QQQ   317.65 (+0.62%)
AAPL   162.73 (+0.23%)
MSFT   283.54 (-0.18%)
META   209.95 (+1.02%)
GOOGL   102.64 (+1.73%)
AMZN   102.63 (+0.62%)
TSLA   200.25 (+2.55%)
NVDA   274.04 (+0.08%)
NIO   10.51 (+0.48%)
BABA   102.47 (-0.88%)
AMD   96.53 (-1.38%)
T   19.11 (+0.16%)
F   12.47 (+1.46%)
MU   61.23 (-2.95%)
CGC   1.78 (+0.85%)
GE   94.93 (+0.94%)
DIS   98.93 (+0.85%)
AMC   4.96 (-0.20%)
PFE   40.54 (+0.40%)
PYPL   74.94 (+0.74%)
NFLX   341.11 (+0.79%)
Top-Rated Stocks  
NASDAQ:PLRX

Pliant Therapeutics - PLRX News Today

$26.52
-0.02 (-0.08%)
(As of 03/31/2023 10:34 AM ET)
Add
Compare
Today's Range
$25.77
▼
$26.82
50-Day Range
$22.51
▼
$36.26
52-Week Range
$3.96
▼
$36.64
Volume
64,760 shs
Average Volume
805,658 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.80
Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.


PLRX Media Mentions By Week

PLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PLRX
News Sentiment
▼
0.76

0.60
▲
Average
Medical
News Sentiment

PLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PLRX Articles
This Week
▼
6

3
▲
PLRX Articles
Average Week

SourceHeadline
MarketBeat logoPliant Therapeutics' (PLRX) "Buy" Rating Reaffirmed at HC Wainwright
americanbankingnews.com - March 31 at 2:34 AM
markets.businessinsider.com logoH.C. Wainwright Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
markets.businessinsider.com - March 28 at 11:11 AM
markets.businessinsider.com logoThe Latest Analyst Ratings for Pliant Therapeutics
markets.businessinsider.com - March 28 at 11:11 AM
finance.yahoo.com logoPliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
finance.yahoo.com - March 27 at 12:40 PM
MarketBeat logoPliant Therapeutics, Inc. (NASDAQ:PLRX) Expected to Earn Q1 2023 Earnings of ($0.54) Per Share
americanbankingnews.com - March 24 at 1:42 AM
MarketBeat logoHC Wainwright Weighs in on Pliant Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:PLRX)
americanbankingnews.com - March 23 at 2:38 AM
msn.com logoPliant gets safety panel nod to test higher dose of bexotegrast in liver disease trial
msn.com - March 13 at 6:00 PM
finance.yahoo.com logoPliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
finance.yahoo.com - March 13 at 9:08 AM
finance.yahoo.com logoPliant Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags
finance.yahoo.com - March 11 at 9:27 AM
markets.businessinsider.com logo9 Analysts Have This to Say About Pliant Therapeutics
markets.businessinsider.com - March 10 at 6:27 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and Pliant Therapeutics (PLRX)
markets.businessinsider.com - March 10 at 7:18 AM
msn.com logoPliant Therapeutics GAAP EPS of -$0.72 misses by $0.02, revenue of $1.97M beats by $0.8M
msn.com - March 9 at 9:17 PM
finance.yahoo.com logoPliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 9 at 9:17 PM
finance.yahoo.com logoPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results
finance.yahoo.com - March 9 at 4:16 PM
finance.yahoo.com logoPliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors
finance.yahoo.com - March 8 at 4:23 PM
finance.yahoo.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) is a favorite amongst institutional investors who own 58%
finance.yahoo.com - March 5 at 6:07 PM
msn.com logoNovartis ends NASH collaboration with Pliant
msn.com - February 24 at 6:30 PM
markets.businessinsider.com logoOppenheimer Keeps Their Buy Rating on Pliant Therapeutics (PLRX)
markets.businessinsider.com - February 24 at 6:30 PM
finance.yahoo.com logoPliant Therapeutics to Participate in Upcoming Investor Events
finance.yahoo.com - February 7 at 8:26 AM
markets.businessinsider.com logoPliant Gets FDA Clearance INDA For PLN-101095 To Treat Solid Tumors
markets.businessinsider.com - February 2 at 10:31 AM
finance.yahoo.com logoTechne (TECH) Q2 Earnings and Revenues Miss Estimates
finance.yahoo.com - February 2 at 10:31 AM
finance.yahoo.com logoPliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
finance.yahoo.com - February 2 at 10:31 AM
finanznachrichten.de logoPliant Therapeutics, Inc.: Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
finanznachrichten.de - January 25 at 12:45 PM
finance.yahoo.com logoPliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
finance.yahoo.com - January 25 at 12:45 PM
finance.yahoo.com logoPliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
finance.yahoo.com - January 25 at 12:45 PM
finanznachrichten.de logoPliant Therapeutics, Inc.: Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
finanznachrichten.de - January 25 at 7:45 AM
finance.yahoo.com logoPliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
finance.yahoo.com - January 25 at 1:46 AM
marketwatch.com logoPliant Therapeutics Shares Touch 52-Week High on Bexotegrast Study >PLRX
marketwatch.com - January 23 at 1:37 PM
markets.businessinsider.com logoNeedham Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
markets.businessinsider.com - January 23 at 1:37 PM
finance.yahoo.com logoBenzinga's Talk of the Town: Top Social Trending Stories You Need To Know
finance.yahoo.com - January 23 at 1:37 PM
finance.yahoo.com logoAn Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 45%
finance.yahoo.com - January 23 at 1:37 PM
msn.com logoSalesforce, Tesla And Other Big Stocks Moving Higher In Monday's Pre-Market Session
msn.com - January 23 at 8:37 AM
msn.com logoPliant stock surges ~50% as drug shows promise in mid-stage study for lung disorder
msn.com - January 23 at 8:37 AM
marketwatch.com logoPliant Therapeutics Shares Surge Premarket on Positive Study Data >PLRX
marketwatch.com - January 23 at 8:37 AM
finance.yahoo.com logoPliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder
finance.yahoo.com - January 23 at 8:36 AM
finance.yahoo.com logoPliant Therapeutics shares rally 75%
finance.yahoo.com - January 23 at 8:36 AM
finance.yahoo.com logoPliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
finance.yahoo.com - January 22 at 3:20 PM
finance.yahoo.com logoStrength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
finance.yahoo.com - January 12 at 8:41 AM
finance.yahoo.com logoPliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:11 AM
finance.yahoo.com logoInvestors in Pliant Therapeutics (NASDAQ:PLRX) have made a return of 19% over the past year
finance.yahoo.com - December 25 at 10:39 AM
seekingalpha.com logoPliant Therapeutics: Wait For More Data Clarity On Dose-Dependent Response In FVC
seekingalpha.com - December 16 at 9:09 AM
finance.yahoo.com logoPliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
finance.yahoo.com - December 15 at 8:47 AM
finance.yahoo.com logoJ.P. Morgan Says These 2 Stocks Could Surge Over 90% From Current Levels
finance.yahoo.com - December 8 at 5:46 PM
finance.yahoo.com logoPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 8 at 5:35 PM
nasdaq.com logoMilestone's (MIST) Tachycardia Study Data Fail to Impress Investors
nasdaq.com - October 18 at 8:58 PM
nasdaq.com logoPliant Therapeutics, Inc. (NASDAQ:PLRX) has caught the attention of institutional investors who hold a sizeable 39% stake
nasdaq.com - October 15 at 3:32 PM
finance.yahoo.com logoPliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
finance.yahoo.com - October 5 at 12:05 PM
finance.yahoo.com logoPliant Therapeutics, Inc.'s (NASDAQ:PLRX) institutional investors lost 12% last week but have benefitted from longer-term gains
finance.yahoo.com - September 26 at 8:00 AM
finance.yahoo.com logoPliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
finance.yahoo.com - September 15 at 8:49 AM
finance.yahoo.com logoStock Market: Dow Jones Up 350 Points; Egg Stock Breaks Out
finance.yahoo.com - September 9 at 3:52 PM
Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:PLRX) was last updated on 3/31/2023 by MarketBeat.com Staff